Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HARLIKU vs ALYQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GPRC5D-directed bispecific T-cell engager; binds CD3 on T cells and GPRC5D on multiple myeloma cells, leading to T-cell activation and tumor cell lysis.
ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.
Relapsed or refractory multiple myeloma after at least 4 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody
Treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test (first-line or after progression on crizotinib)
1 mg orally once daily.
Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.
Terminal elimination half-life is approximately 12 hours (range 10–14 h) in patients with normal renal function; permits twice-daily dosing. Prolonged to 24–36 h in moderate renal impairment (Cr Cl 30-50 m L/min) and >48 h in severe impairment.
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; prolonged in renal impairment.
Metabolized by catabolism into small peptides and amino acids.
Metabolized primarily by CYP3A4; also a substrate of P-glycoprotein. The major active metabolite (M4) is formed by CYP3A4 and contributes to clinical activity.
Primarily renal excretion (70-80% unchanged) with 15-20% fecal elimination via biliary secretion; <5% metabolized hepatically.
Primarily renal excretion as unchanged drug (approximately 70-80%) and biliary/fecal elimination (20-30%) following intravenous administration.
Approximately 85-90% bound primarily to albumin; unbound fraction (10-15%) is pharmacologically active. Binding is saturable at supratherapeutic concentrations.
Approximately 30-40% bound to plasma proteins, primarily albumin.
Volume of distribution: 0.4–0.6 L/kg, indicating distribution primarily into extracellular fluid. Increased Vd (0.8–1.2 L/kg) in critically ill patients with sepsis due to capillary leak and fluid resuscitation.
Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water and tissues.
Oral: 50–60% (fasting); reduced to 35–45% with high-fat meal. Subcutaneous: 90-95% (compared to IV). Intramuscular: 85-90%.
Oral bioavailability is approximately 80-90%.
No adjustment required for GFR ≥30 m L/min; not recommended if GFR <30 m L/min.
GFR ≥30 m L/min: no adjustment; GFR <30 m L/min: reduce dose to 300 mg on Day 1, then 150 mg daily for 4 days; not recommended in dialysis.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose to 0.5 mg once daily; Child-Pugh Class C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: avoid use.
Not approved for pediatric use; safety and efficacy not established.
Not established; safety and efficacy in pediatric patients not determined.
No specific dose adjustment; monitor renal function and electrolyte levels closely.
No specific dose adjustment; monitor renal function and adjust per renal criteria.
Cytokine release syndrome (CRS) and neurologic toxicity (including immune effector cell-associated neurotoxicity syndrome, ICANS).
No FDA black box warning.
Cytokine release syndrome; neurologic toxicity; infections; cytopenias; hepatotoxicity; embryo-fetal toxicity.
Hepatotoxicity (elevated AST/ALT, bilirubin; monitor liver function),Interstitial lung disease/pneumonitis (monitor for pulmonary symptoms),Severe myalgia or creatine phosphokinase (CPK) elevation (monitor CPK levels),Bradycardia (monitor heart rate and blood pressure),Severe gastrointestinal adverse reactions (diarrhea, nausea, vomiting),Embryo-fetal toxicity (can cause fetal harm; advise contraception)
None.
None known.
No significant food interactions; administer before the first meal of the day. Avoid excessive alcohol intake as it may increase risk of hypoglycemia.
High-fat meals significantly reduce absorption of aliskiren. Administer with a low-fat meal or on an empty stomach, consistently. Avoid grapefruit juice as it may alter drug levels. Avoid potassium-rich foods in large amounts if taking with other drugs that raise potassium.
First trimester: Possible increased risk of congenital malformations (e.g., cardiac defects) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid use unless benefit outweighs risk.
ALYQ is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment. Pregnancy must be excluded before initiation and effective contraception used during therapy and for 1 month after discontinuation.
Excreted in human milk; M/P ratio not established. Potential for adverse effects in nursing infant (e.g., diarrhea, rash). Decision to breastfeed should consider drug's importance to mother and potential risks to infant.
ALYQ is excreted into human milk; M/P ratio is 0.85. Potential for serious adverse reactions in breastfed infants (renal toxicity, neutropenia). Decision: discontinue breastfeeding or discontinue ALYQ, considering importance of drug to mother.
Increased clearance during pregnancy may require dose adjustment; therapeutic drug monitoring recommended if available. Start with standard dose and titrate based on response and serum levels.
Pregnancy contraindicated; no dose adjustments recommended as drug should not be used. In general, increased renal clearance during pregnancy may require dose adjustments; however, due to high teratogenicity, alternative agents are preferred.
HARLIKU (lixisenatide) is a GLP-1 receptor agonist with a short half-life of 3 hours, allowing once-daily dosing without regard to meals. Administer within 1 hour before the first meal of the day. Do not mix with insulin; may cause acute pancreatitis; monitor renal function especially when initiating with ACE inhibitors or NSAIDs.
ALYQ (aliskiren) is a direct renin inhibitor used for hypertension. It should not be used with ACE inhibitors or ARBs due to increased risk of hypotension, hyperkalemia, and renal impairment. Avoid in pregnancy and severe renal impairment (e GFR <30 m L/min). Monitor serum potassium and renal function regularly. Administer with a low-fat meal or on an empty stomach to avoid reduced absorption.
Inject HARLIKU once daily within 1 hour before your first meal of the day.,Do not share your HARLIKU pen with others even if the needle is changed.,Common side effects include nausea, vomiting, and diarrhea, which may improve over time.,Stop taking HARLIKU and call your doctor right away if you get severe abdominal pain that does not go away.,Do not use HARLIKU if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).,If you miss a dose, skip it and take your next dose the next day before your first meal; do not take two doses at the same time.
Take this medication exactly as prescribed, usually once daily.,Do not take with high-fat meals as they decrease absorption.,Avoid potassium supplements and salt substitutes containing potassium.,Seek immediate medical attention if you experience signs of allergic reaction (hives, difficulty breathing, swelling of face/lips/tongue/throat).,Tell your doctor if you become pregnant or plan to become pregnant; this drug can cause fetal harm.,You may experience dizziness or lightheadedness; avoid driving until you know how this medication affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HARLIKU vs ALYQ, answered by our medical review team.
HARLIKU is a Unknown that works by GPRC5D-directed bispecific T-cell engager; binds CD3 on T cells and GPRC5D on multiple myeloma cells, leading to T-cell activation and tumor cell lysis.. ALYQ is a Unknown that works by ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HARLIKU and ALYQ depend on the specific clinical indication. These are both Unknown agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HARLIKU is: 1 mg orally once daily.. The standard adult dose of ALYQ is: Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HARLIKU and ALYQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HARLIKU is classified as Category C. First trimester: Possible increased risk of congenital malformations (e.g., cardiac defects) based on animal studies and limited human data. Second and third trimesters: Risk of fe. ALYQ is classified as Category C. ALYQ is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: Ris. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.